kabutan

Medrx Co.,Ltd.(4586) Summary

4586
TSE Growth
Medrx Co.,Ltd.
108
JPY
+2
(+1.89%)
Mar 13, 3:30 pm JST
0.67
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
106.1
Mar 13, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.22
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
106 JPY 0.66 USD
Previous Close Mar 12
106 JPY 0.66 USD
High Mar 13, 3:19 pm
109 JPY 0.68 USD
Low Mar 13, 9:06 am
104 JPY 0.65 USD
Volume
747,300
Trading Value
0.08B JPY 0.50M USD
VWAP
106.13 JPY 0.67 USD
Minimum Trading Value
10,800 JPY 67 USD
Market Cap
6.41B JPY 0.04B USD
Number of Trades
204
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
904
1-Year High Sep 29, 2025
32,058
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 1,800 7,362,600 4090.33
Feb 27, 2026 0 5,663,400
Feb 20, 2026 0 5,939,600
Feb 13, 2026 0 6,191,600
Feb 6, 2026 0 6,321,900
Company Profile
Medrx Co., Ltd. is a drug discovery venture company with strengths in transdermal drug delivery system technologies and microneedle array technology.
Sector
Pharmaceuticals
Medrx Co., Ltd. aims to create new value-added pharmaceuticals through its proprietary transdermal drug delivery system technologies, primarily ILTS and NCTS. These technologies maximize drug efficacy, reduce side effects, and enable drug administration to patients who have difficulty with oral intake. One of the company's main development pipelines, MRX-5LBT for the treatment of post-herpetic neuralgia, received a Complete Response Letter from the FDA in September 2023. Other pipelines include MRX-4TZT for spastic paralysis, MRX-9FLT for central analgesic, and MRX-7MLL for Alzheimer's disease. Additionally, the company is developing microneedle technology, a vaccine delivery device that allows for painless self-administration. Medrx Co., Ltd. is expanding globally through its U.S. subsidiary and is promoting development and commercialization through partnerships with pharmaceutical companies and other entities.